Elenco dei centri specialistici della Regione Piemonte, per la cura […]
Search Results for: Un gel intelligente per attaccare il cancro
Here's what we've found for you
Italiani scoprono un nuovo biomarcatore del cancro gastrico
Ricercatori Biogem, si apre la strada a cure mirate
Italiani scoprono un nuovo biomarcatore del cancro gastrico
Ricercatori Biogem, si apre la strada a cure mirate
Multicentre RCT of a self-assembling haemostatic gel to prevent delayed bleeding following EMR–an underpowered sample size calculation
We read the study conducted by Drews et al1 with great interest. In this prospective randomised controlled trial of patients undergoing hot-snare EMR of flat lesions in the duodenum (≥10 mm) and colorectum (≥20 mm) at 15 German centres, the authors conclude that the application of a haemostatic gel (Purastat, 3-D Matrix Europe SAS) following EMR in both locations does not reduce the rate of delayed bleeding (DB). From a conceptual perspective, combining two anatomical sites with likely different pathophysiologies of DB and different bleeding rates and assuming the likely percentage distribution spread for the lesion location of the cases enrolled seems to us to be a suboptimal design for a randomised clinical trial. Aside from this design, which could be subject to debate, our main objection to the trial is the sample size calculation. Reviewing the results of the three colonic RCTs referenced by the authors
La “pillola su filo” per monitorare l’esofago di Barrett riduce le endoscopie
Un nuovo test con capsula e spugna, molto meno invasivo, […]
Tumori, creato un test che prevede se cancro resisterà a chemio
Consentirà di personalizzare cure sin dal momento della diagnosi
La partita più bella del mondo con i ragazzi guariti dal cancro
In campo squadre dei Centri oncoematologia pediatrica d’Italia
Multicentre randomised controlled trial of a self-assembling haemostatic gel to prevent delayed bleeding following endoscopic mucosal resection (PURPLE Trial)
Background
Prophylactic application of a haemostatic gel to the resection field may be an easy way to prevent delayed bleeding, a frequent complication after endoscopic mucosal resection (EMR).
Objective
We aimed to evaluate if the prophylactic application of a haemostatic gel to the resection field directly after EMR can reduce the rate of clinically significant delayed bleeding events.
Design
We conducted a prospective randomised trial of patients undergoing hot-snare EMR of flat lesions in the duodenum (≥10 mm) and colorectum (≥20 mm) at 15 German centres. Prophylactic clip closure was not allowed, but selective clipping or coagulation could be used prior to randomisation to treat intraprocedural bleeding or for prophylactic closure of visible vessels. Patients were randomised to haemostatic gel application or no prophylaxis. The primary endpoint was delayed bleeding within 30 days.
Results
The trial was stopped early due to futility after an interim analysis. The primary endpoint was analysed in 232 patients (208 colorectal, 26 duodenal). Both groups were comparable in age, sex, comorbidities and lesion characteristics. Preventive measures, such as selective clipping or coagulation, were applied prior to randomisation in 51.9% of cases, with no difference between groups. Delayed bleeding occurred in 14 cases (11.7%; 95% CI 7.1% to 18.6%) after Purastat and in 7 cases (6.3%; 95% CI 3.1% to 12.3%) in the control group (p=0.227), with no difference between colorectal and duodenal subgroups.
Conclusion
The application of a haemostatic gel following EMR of large flat lesions in the duodenum and colorectum does not reduce the rate of delayed bleeding.
Multicentre randomised controlled trial of a self-assembling haemostatic gel to prevent delayed bleeding following endoscopic mucosal resection (PURPLE Trial)
Background
Prophylactic application of a haemostatic gel to the resection field may be an easy way to prevent delayed bleeding, a frequent complication after endoscopic mucosal resection (EMR).
Objective
We aimed to evaluate if the prophylactic application of a haemostatic gel to the resection field directly after EMR can reduce the rate of clinically significant delayed bleeding events.
Design
We conducted a prospective randomised trial of patients undergoing hot-snare EMR of flat lesions in the duodenum (≥10 mm) and colorectum (≥20 mm) at 15 German centres. Prophylactic clip closure was not allowed, but selective clipping or coagulation could be used prior to randomisation to treat intraprocedural bleeding or for prophylactic closure of visible vessels. Patients were randomised to haemostatic gel application or no prophylaxis. The primary endpoint was delayed bleeding within 30 days.
Results
The trial was stopped early due to futility after an interim analysis. The primary endpoint was analysed in 232 patients (208 colorectal, 26 duodenal). Both groups were comparable in age, sex, comorbidities and lesion characteristics. Preventive measures, such as selective clipping or coagulation, were applied prior to randomisation in 51.9% of cases, with no difference between groups. Delayed bleeding occurred in 14 cases (11.7%; 95% CI 7.1% to 18.6%) after Purastat and in 7 cases (6.3%; 95% CI 3.1% to 12.3%) in the control group (p=0.227), with no difference between colorectal and duodenal subgroups.
Conclusion
The application of a haemostatic gel following EMR of large flat lesions in the duodenum and colorectum does not reduce the rate of delayed bleeding.
ESMO: scala aggiornata per misurare il beneficio clinico dei trattamenti contro il cancro
L’European Society for Medical Oncology (ESMO) ha pubblicato l’ultima versione della […]
In Italia 441 giorni di attesa per l'accesso alle nuove cure contro i tumori
Ostacoli anche dai prontuari terapeutici. Ritardi territoriali per la cura innovativa nel cancro della prostata
Vincitore Pezcoller, 'importante capire forme resistenza cancro'
“Abbiamo capito che non esistono cure miracolose”
La Nave Vespucci a Napoli contro il cancro al polmone
La Campania la regione con più fumatori e sedentari
Giovani donne più a rischio di cancro, colpa di alcol e fumo
L’incidenza di certi tumori più alta rispetto ai coetanei maschi
Le statine possono migliorare la sopravvivenza nei pazienti con alcuni tumori del sangue
L’uso di statine, farmaci ampiamente utilizzati per abbassare il colesterolo, […]
Identificata una nuova immunoterapia mirata per il cancro ovarico
I ricercatori della Mayo Clinic hanno scoperto che un nuovo bersaglio dell’immunoterapia, […]